These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28490047)

  • 1. Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma.
    van Nuland M; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH
    Ther Drug Monit; 2017 Jun; 39(3):243-251. PubMed ID: 28490047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS.
    Kim KP; Parise RA; Holleran JL; Lewis LD; Appleman L; van Erp N; Morris MJ; Beumer JH
    J Pharm Biomed Anal; 2017 May; 138():197-205. PubMed ID: 28219796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma.
    van Nuland M; Rosing H; de Vries J; Ovaa H; Schellens JHM; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Nov; 1068-1069():119-124. PubMed ID: 29059586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LC-MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide.
    van Nuland M; Venekamp N; Wouters WME; van Rossum HH; Rosing H; Beijnen JH
    J Pharm Biomed Anal; 2019 Jun; 170():161-168. PubMed ID: 30925273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology.
    van Nuland M; Venekamp N; de Vries N; de Jong KAM; Rosing H; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Feb; 1106-1107():26-34. PubMed ID: 30639947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma.
    Benoist GE; van der Meulen E; Lubberman FJE; Gerritsen WR; Smilde TJ; Schalken JA; Beumer JH; Burger DM; van Erp NP
    Biomed Chromatogr; 2017 Nov; 31(11):. PubMed ID: 28370076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous determination of abiraterone and its five metabolites in human plasma by LC-MS/MS: Application to pharmacokinetic study in healthy Chinese subjects.
    Hu Y; Wu J; Jiang X; Chen G; Zhang Y; Si L; Jiang H; Huang J; Huang J
    J Pharm Biomed Anal; 2022 Aug; 217():114826. PubMed ID: 35576735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An LC-MS/MS method for quantification of abiraterone, its active metabolites D(4)-abiraterone (D4A) and 5α-abiraterone, and their inactive glucuronide derivatives.
    Caron P; Turcotte V; Lévesque E; Guillemette C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1104():249-255. PubMed ID: 30537624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring.
    Llopis B; Robidou P; Tissot N; Pinna B; Gougis P; Aubart FC; Campedel L; Abbar B; Weil DR; Uzunov M; Gligorov J; Salem JE; Funck-Brentano C; Zahr N
    J Pharm Biomed Anal; 2021 Apr; 197():113968. PubMed ID: 33618135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and ∆(4)-abiraterone from cancer patients.
    Bhatnagar A; McKay MJ; Thaysen-Andersen M; Arasaratnam M; Crumbaker M; Gurney H; Molloy MP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Sep; 1126-1127():121741. PubMed ID: 31421381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer.
    Puszkiel A; Plé A; Huillard O; Noé G; Thibault C; Oudard S; Goldwasser F; Vidal M; Alexandre J; Blanchet B
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jul; 1058():102-107. PubMed ID: 28545929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A quick UPLC-MS/MS method for therapeutic drug monitoring of abiraterone and delta(4)-abiraterone in human plasma.
    Weiss TLD; Furtado CM; Antunes MV; Gössling G; Schwartsmann G; Linden R; Verza SG
    Biomed Chromatogr; 2020 Nov; 34(11):e4947. PubMed ID: 32652651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of an LC-MS/MS method for simultaneous quantification of abiraterone, enzalutamide and darolutamide in human plasma.
    Buck SAJ; de Bruijn P; Ghobadi-Moghaddam-Helmantel IM; Lam MH; de Wit R; Koolen SLW; Mathijssen RHJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Jun; 1225():123752. PubMed ID: 37269569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.
    Herbrink M; de Vries N; Rosing H; Huitema ADR; Nuijen B; Schellens JHM; Beijnen JH
    Biomed Chromatogr; 2018 Apr; 32(4):. PubMed ID: 29165815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a novel LC-MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column.
    Alyamani M; Li Z; Upadhyay SK; Anderson DJ; Auchus RJ; Sharifi N
    J Steroid Biochem Mol Biol; 2017 Sep; 172():231-239. PubMed ID: 27063554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Benoist GE; van der Meulen E; van Oort IM; Beumer JH; Somford DM; Schalken JA; Burger DM; van Erp NP
    Ther Drug Monit; 2018 Apr; 40(2):222-229. PubMed ID: 29419723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative determination of enzalutamide, an anti-prostate cancer drug, in rat plasma using liquid chromatography-tandem mass spectrometry, and its application to a pharmacokinetic study.
    Song JH; Kim TH; Jung JW; Kim N; Ahn SH; Hwang SO; Kang NS; Yoo SE; Koo TS
    Biomed Chromatogr; 2014 Aug; 28(8):1112-7. PubMed ID: 24424891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a method for quantifying enzalutamide and its major metabolites in human plasma by LC-MS/MS.
    Bennett D; Gibbons JA; Mol R; Ohtsu Y; Williard C
    Bioanalysis; 2014 Mar; 6(6):737-44. PubMed ID: 24328824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel LC-MS/MS method for the simultaneous quantification of topiramate and its main metabolites in human plasma.
    Milosheska D; Roškar R
    J Pharm Biomed Anal; 2017 May; 138():180-188. PubMed ID: 28214451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A validated liquid chromatographic-tandem mass spectroscopy method for the quantification of abiraterone acetate and abiraterone in human plasma.
    Martins V; Asad Y; Wilsher N; Raynaud F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Nov; 843(2):262-7. PubMed ID: 16809076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.